Indicators in View on Shares of Bio-Rad Laboratories (BIO) — Investing Focus

Ceria Alfonso
Enero 13, 2018

(NYSE:BIO) by 4.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The stock of Bio-Rad Laboratories, Inc. BIO's profit will be $37.98 million for 49.41 P/E if the $1.27 EPS becomes a reality.

Looking at shares from a technical standpoint, Bio-Rad Laboratories (BIO) presently has a 14-day Commodity Channel Index (CCI) of 65.06. The number of shares now owned by investors are 34.59 mln. Pacad Investment Ltd. bought a new position in Bio-Rad Laboratories during the second quarter valued at $113,000. Capstone Advsr Limited Liability holds 0.01% or 1,300 shares in its portfolio.

A number of research analysts recently issued reports on BIO shares. Deutsche Bank reaffirmed a "buy" rating and set a $255.00 target price on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. Zacks Investment Research raised shares of Bio-Rad Laboratories from a "sell" rating to a "hold" rating in a research note on Wednesday, October 4th. They use historic price data to observe stock price patterns to predict the direction of that price going forward. Robert W. Baird upgraded shares of Aecom from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $40.00 to $45.00 in a research report on Wednesday, January 3rd.

More news: Sarepta Therapeutics, Inc. (SRPT) Recent Ownership Changes

Analysts await Bio-Rad Laboratories, Inc. Bio-Rad Laboratories, Inc. has a one year low of $122.96 and a one year high of $194.20. Bio-Rad Laboratories, Inc. The stock has a market capitalization of $8,620.00, a price-to-earnings ratio of 312.25, a PEG ratio of 2.01 and a beta of 0.97. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.20 and a quick ratio of 1.20. CL King initiated the shares of BIO in report on Thursday, October 13 with "Buy" rating. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. (NYSE:BIO). Canada Pension Plan Inv Board stated it has 5,100 shares.

Aecom (NYSE:ACM) Director Rob J. Routs sold 6,468 shares of the business's stock in a transaction dated Wednesday, December 26th. The shares were sold at an average price of $171.42, for a total transaction of $222,674.58. Over the last ninety days, insiders sold 9,126 shares of company stock valued at $2,309,426. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Wells Fargo & Company MN now owns 546,029 shares of the company's stock valued at $89,445,000 after buying an additional 2,870 shares during the last quarter. The disclosure for this sale can be found here. The insider TSINGOS CHRISTINE A sold 4,980 shares worth $1.24M. Institutional investors and hedge funds own 63.88% of the company's stock. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions. D E Shaw And Comm has invested 0% in Bio-Rad Laboratories, Inc. TIAA CREF Investment Management LLC raised its stake in Bio-Rad Laboratories by 7.4% in the third quarter. First Manhattan Co. now owns 599 shares of the medical research company's stock worth $133,000 after purchasing an additional 250 shares in the last quarter. (NYSE:BIO). Advisors Asset Management Inc has invested 0.07% of its portfolio in Bio-Rad Laboratories, Inc. Meeder Asset Management Inc. now owns 618 shares of the medical research company's stock worth $137,000 after purchasing an additional 600 shares in the last quarter. After $0.91 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 39.56% EPS growth. The fund owned 28,042 shares of the medical research company's stock after acquiring an additional 1,112 shares during the period.

COPYRIGHT VIOLATION NOTICE: "Brokerages Anticipate Bio-Rad Laboratories, Inc". The company had revenue of $4.86 billion for the quarter, compared to the consensus estimate of $4.63 billion. If you are accessing this news story on another website, it was illegally copied and republished in violation of USA and global copyright legislation. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. The firm operates through two divisions, Life Science and Clinical Diagnostics. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Otros informes por

Discuta este artículo